<DOC>
	<DOCNO>NCT00064974</DOCNO>
	<brief_summary>This study multi-center , single-arm , open-label study oral CC-5013 monotherapy administer dose 10 mg daily Days 1-21 every 28 day ( 28-day cycle ) red blood cell ( RBC ) transfusion-dependent subject low- intermediate-1-risk MDS del ( 5q31-33 ) cytogenetic abnormality . Screening procedure take place within 28 day first day study drug treatment . Subjects receive study drug ( CC-5013 ) 28-day cycle 6 cycle , bone marrow disease progression progression/relapse follow erythroid hematologic improvement ( Appendix I ) document . Study visit occur every cycle ( every 28 day ) laboratory monitor assess hematological parameter occur every 14 day . Safety efficacy assessment perform study outline Schedule Study Assessments .</brief_summary>
	<brief_title>Efficacy Safety Study CC-5013 Monotherapy Subjects With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Age ≥ 18 year time signing informed consent form . Must able adhere study visit schedule protocol requirement . Diagnosis low intermediate1risk IPSS ( Appendix III ) MDS without abnormality chromosome 5 involve deletion band q31 q33 . Red blood cell ( RBC ) transfusiondependent anemia define receive ≥ 2 unit RBCs within 8 week first day study drug treatment . Eastern Cooperative Oncology Group ( ECOG ) ( Appendix IV ) performance status score 0 , 1 , 2 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . Sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug . Pregnant lactating female . Prior therapy lenalidomide . An abnormality chromosome 5 involve deletion band q31 q33 . Lab Abnormality : Absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 ( 0.5 x 109/L ) Lab Abnormality : Platelet count &lt; 50,000/mm3 ( 50 x 109/L ) Lab Abnormality : Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) Lab Abnormality : Serum glutamic oxaloacetic transaminase/Aspartate transaminase ( SGOT/AST ) Serum glutamic pyruvic transaminase/Alanine transaminase ( SGPT/ALT ) &gt; 3.0 x upper limit normal ( ULN ) Lab Abnormality : Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) Prior ≥ grade 3 National Cancer Institute ( NCI ) Common Toxicity Criteria ( CTC ) ( Appendix VI ) allergic reaction/hypersensitivity thalidomide . Prior ≥ grade 3 NCI CTC ( Appendix VI ) rash desquamation ( blister ) take thalidomide . Clinically significant anemia due factor iron , B12 folate deficiency , autoimmune hereditary hemolysis gastrointestinal bleeding If marrow aspirate evaluable storage iron , transferrin saturation must &gt; 20 % serum ferritin le 50 ng/mL . Use hematopoietic growth factor within 7 day first day study drug treatment . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 28 day first day study drug treatment . Use experimental standard drug ( i.e . chemotherapeutic , immunosuppressive , cytoprotective agent ) treatment MDS within 28 day first day study drug treatment . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease great equal 3 year . Use experimental therapy within 28 day first day study drug treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Celgene</keyword>
</DOC>